‘Should I Take HRT,Doctor?’ Hormone Replacement Therapy in Women at Increased Risk of Breast Cancer and in Survivors of the Disease

Alpers CE Wellings SR . The prevalence of carcinoma in situ in normal and cancer associated breasts. Human Pathology 1985; 16: 796–807

Anderson TJ Battersby S King RJB McPherson K Going JJ . Oral contraceptive use influences resting breast proliferation. Human Pathology 1989; 20: 1139–1144

Armstrong BK . Oestrogen therapy after the menopause — boon or bane? Med J Aust 1988; 148: 213–214.

Bergkvist L Adami H-G Persson In Bergstrom R Krusemo UB . Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidem 1989; 130: 221–228.

Blair V. Breast cancer and oestrogen therapy. JAMA 1994; 272: 104.

Bonnier P Romain S Giacalone PL Laffargue F Martin PM Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995; 85: 11–17.

Brinton LA Hoover R Fraumeni JF Menopausal oestrogens and breast cancer risk: an expanded case control study. Br J Cancer. 1986; 54: 825–832.

Claus EB Risch N Thompson D. Autosomal dominant inheritance of early-onset breast cancer. Cancer 1994; 3: 643–651.

Cobleigh MA Berris RF Bush T Davidson NE Robert NJ Sparano JA Estrogen replacement therapy in breast cancer survivors. JAMA 1994; 272: 540–545.

Colditz GA Egan KM Stampfer MJ Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynaecol 1993; 168: 1473–1480.

Colditz GA Stampfer MJ Willett WC Type of postmenopausal hormone use and risk of breast cancer: 12 year follow-up from the Nurses Health Study. CA Causes Control 1992; 3: 433–439.

Colditz GA Hankinson SE Hunter DJ Willett WC Manson JE Stampfer MJ Hennekens C Rosner B Speizer FE The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Eng J Med 1995; 332: 1589–1593

Criqui MH Suarez L Barrett-Connor E McPhillips JW Garbard C. Postmentopausal oestrogen use and mortality. Am J Epidemiology 1988; 128: 606–614.

Dao TL Sirha DDK Nemoto T Patel J. Effect of estrogen and progesterone on tumour labelling index of breast cancer. Cancer Res. 1982; 42: 259–362.

Dhodapkar MV Ingle JN Ahmann DL Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 1995; 75: 43–46.

Di Saia PJ Odicino F Grosen EA Cowan B Pecorell S Wile AG Hormone replacement therapy in breast cancer. Lancet 1993; 342: 1232.

Dupont WD Page DL Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67–72.

Dupont WD Page DL Rogers LW Parl FF Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 1989; 63: 948–957.

Eden JA Bush T Nand S Wren BG A case-controlled study of combined continuous oestrogen-progestogen replacement therapy amongst women with a personal history of breast cancer. Menopause — The Journal of the North American Menopause Society 1995; 2: 67–72

Grady D Rubin SM Petitti DB Fox CS Black D Ettinger B Ernster VL Cummings S. Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals Intern Med 1992; 117: 1016–1037

Henderson BE Paganini-Hill A Ross RK Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 1551: 75–78.

Hoover R Glass G Fiinkle WD Azevedo D Milne K. Conjugated estrogens and breast cancer risk in women. J Nat Cancer Inst. 1981; 67: 815–820.

Howell A Dodwell D Anderson H Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Annals of Oncology 1992; 3: 611–617.

Hunt K Vessey M McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. Br J Obstet Gynaecol 1990; 97: 1080–1086.

Kaufmann DW Miller DR Rosenberg L Noncontraceptive estrogen use and the risk of breast cancer. JAMA 1984; 252: 63–67.

Kaufman DW Palmer JR deMouzon J Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol. 1991; 134: 1375–1385.

Laidlaw I Anderson E Clarke R Potten CS Howell A. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by oestrogen but not pregesterone. Endocrinology 1995; 136: 164–171.

La Vecchia C Decarli A Parazzini F Gentile A Liberati C Franceschi S. Non-contraceptive oestrogens and the risk of breast cancer in women. Int. J. Cancer 1986; 38: 853–858.

La Vecchia C Negri E Franceschi S Favero A Nanni O Filiberti R Conti E Montella M Veronesi A Ferraroni M Decarli A. Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Cancer 1995; 72: 244–248.

McManus MJ Welsch CW The effect of estrogen, progesterone, thyroxine and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer 54; 1920–1927

Natchtigall MJ Smillen SW Natchtigall RD Natchtigall RH Natchtigall LE Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992; 80: 827–830

Nielson M Christensen L Anderson J. Contralateral cancerous breast lesions in women with clinical invasive breast carcinoma. Cancer 1986; 57: 897–903.

Nomura AMY Kolonel LN Hirohata T Lee J. The association of replacement estrogens with breast cancer. Int. J. Cancer. 1986; 37: 49–53.

Potten CS Watson RJ Williams GT Tickle S Roberts SA Harrie M Howell A. Cell proliferation in the normal human breast. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988; 58: 631–634.

Powles TJ Hicklish T Casey S O'Brian M. Hormone replacement after breast cancer. Lancet 1993; 342: 60–61.

Powles TJ Hickish TF Kanis JA Ashley S. Tamoxifen preserves bone mineral density in post-menopausal women but causes loss of bone density in premenopausal women. Proceedings ASCO 1995; 14: Abs 344 p 165.

Sillero-Arenas M Delgado-Rodriguez M Rodigues-Canteras R Bueno-Cavanillas A Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 1992; 79: 286–294.

Schairer C Byrne C Keyl PM Brinton LA Sturgeon SR Hoover RN Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes and Control 1994; 5: 491–500.

Squitieri R Tartter PI Ahmed S Brower ST Theise ND Carcinoma of the breast in postmenopausal hormone user and non-user control groups. J Am Coll Surg 1994; 178: 167–170.

Stanford JL Weiss NS Voigt LF Daling JR Habel LA Rossing MA Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137–142.

Steinberg KK Thacker SB Smith SJ Stroup DF Zack MM Flanders WD Berkelman RL A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985–1990.

Steinberg KK Jay Smith S. Breast cancer and oestrogen therapy. JAMA 1994; 272: 1004–1005.

Steinberg KK Smith SJ Thacker SB Stroup DF Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 1994; 5: 415–421.

Stoll BA Effect of Lyndiol, an oral contraceptive, on breast cancer. Br Med J 1967; 1: 150–153.

Stoll BA Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 1989; 25: 1909–1913.

Strickland DM Gambrell RD Butzin CA Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992; 80: 400–404.

Theriault RL Sellin RV A clinical dilemma: Estrogen replacement therapy in postmenopausal women with a background of primary breast cancer. Annals of Oncology 1991; 2: 709–717.

Wile AG Opfell RW Margileth DA Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165: 372–375.

Williams G Anderson E Howell A Watson R Coyne J Roberts SA Porten C. Oral contraceptive use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991; 48: 206–210.